Oslo, 30 September 2020: The board of directors of Navamedic ASA (the “Company”), has today, on 30 September 2020, pursuant the authorisation granted to it by the general meeting on 3 June 2020, resolved to increase the Company’s share capital by NOK 92,500 by issuance of 125,000 new shares, each with a nominal value of NOK 0.74, in order to facilitate today’s exercise of 125,000 share options by the Company’s CEO, Kathrine Gamborg Andreassen. The exercised share options were granted in May 2019 and have, following the completion of the demerger in October 2019, a strike price of NOK 8.88 per share. The new shares to be issued are subject to a 24 months lock-up period, subject to certain exemptions, from the date the shares are received by the option holder.
Following the registration of the share capital increase with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret), the Company’s share capital will be NOK 11,315,994.90, divided into 15,291,885 shares, each with a nominal value of NOK 0.74.
For further information, please contact:
Lars Hjarrand, CFO, Navamedic,
Mobile: +47 917 62 842
Navamedic ASA is a preferred, full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com
This information is published pursuant to the continuing obligations of the Oslo Stock Exchange.